vs
Assertio Holdings, Inc.（ASRT）与BayCom Corp（BCML）财务数据对比。点击上方公司名可切换其他公司
BayCom Corp的季度营收约是Assertio Holdings, Inc.的1.9倍（$25.9M vs $13.5M），BayCom Corp同比增速更快（9.4% vs -57.9%），过去两年BayCom Corp的营收复合增速更高（2.9% vs -35.4%）
Assertio Therapeutics是一家美国专业制药企业，主要聚焦神经病学、疼痛以及中枢神经系统疾病领域的产品销售与推广。公司前身Depomed成立于1995年，总部位于加利福尼亚州纽瓦克，拥有多款获美国FDA批准的产品，目前在纳斯达克上市。
BayCom Corp是总部位于美国的银行控股公司，旗下拥有海湾商业银行，主要服务北加州地区的中小微企业与零售客户，提供商业贷款、存款产品、个人银行、财富管理等多元金融服务，深耕本土社区金融市场。
ASRT vs BCML — 直观对比
营收规模更大
BCML
是对方的1.9倍
$13.5M
营收增速更快
BCML
高出67.3%
-57.9%
两年增速更快
BCML
近两年复合增速
-35.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.5M | $25.9M |
| 净利润 | — | $6.9M |
| 毛利率 | — | — |
| 营业利润率 | -86.7% | 36.6% |
| 净利率 | — | 26.5% |
| 营收同比 | -57.9% | 9.4% |
| 净利润同比 | — | 12.1% |
| 每股收益（稀释后） | $-4.54 | $0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASRTBCML
| Q4 25 | $13.5M | $25.9M | ||
| Q3 25 | $49.5M | $25.7M | ||
| Q2 25 | $29.2M | $24.7M | ||
| Q1 25 | $26.5M | $24.3M | ||
| Q4 24 | $32.2M | $23.7M | ||
| Q3 24 | $29.2M | $25.6M | ||
| Q2 24 | $31.1M | $23.8M | ||
| Q1 24 | $32.4M | $24.5M |
净利润ASRTBCML
| Q4 25 | — | $6.9M | ||
| Q3 25 | $11.4M | $5.0M | ||
| Q2 25 | $-16.4M | $6.4M | ||
| Q1 25 | $-13.5M | $5.7M | ||
| Q4 24 | — | $6.1M | ||
| Q3 24 | $-2.9M | $6.0M | ||
| Q2 24 | $-3.7M | $5.6M | ||
| Q1 24 | $-4.5M | $5.9M |
营业利润率ASRTBCML
| Q4 25 | -86.7% | 36.6% | ||
| Q3 25 | 23.2% | 26.3% | ||
| Q2 25 | -27.5% | 35.3% | ||
| Q1 25 | -50.0% | 31.6% | ||
| Q4 24 | -41.9% | 34.2% | ||
| Q3 24 | -10.4% | 32.4% | ||
| Q2 24 | -11.6% | 31.9% | ||
| Q1 24 | -13.4% | 33.3% |
净利率ASRTBCML
| Q4 25 | — | 26.5% | ||
| Q3 25 | 23.1% | 19.5% | ||
| Q2 25 | -56.0% | 25.8% | ||
| Q1 25 | -51.1% | 23.4% | ||
| Q4 24 | — | 25.9% | ||
| Q3 24 | -10.0% | 23.5% | ||
| Q2 24 | -11.8% | 23.6% | ||
| Q1 24 | -13.9% | 24.0% |
每股收益（稀释后）ASRTBCML
| Q4 25 | $-4.54 | $0.63 | ||
| Q3 25 | $0.11 | $0.46 | ||
| Q2 25 | $-0.17 | $0.58 | ||
| Q1 25 | $-0.14 | $0.51 | ||
| Q4 24 | $-3.28 | $0.55 | ||
| Q3 24 | $-0.03 | $0.54 | ||
| Q2 24 | $-0.04 | $0.50 | ||
| Q1 24 | $-0.05 | $0.51 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.4M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $94.0M | $338.6M |
| 总资产 | $267.0M | $2.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASRTBCML
| Q4 25 | $63.4M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $98.2M | — | ||
| Q1 25 | $87.3M | — | ||
| Q4 24 | $100.1M | — | ||
| Q3 24 | $88.6M | — | ||
| Q2 24 | $88.4M | — | ||
| Q1 24 | $80.7M | — |
总债务ASRTBCML
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $38.6M | — |
股东权益ASRTBCML
| Q4 25 | $94.0M | $338.6M | ||
| Q3 25 | $105.8M | $334.3M | ||
| Q2 25 | $93.3M | $330.6M | ||
| Q1 25 | $108.5M | $329.3M | ||
| Q4 24 | $121.1M | $324.4M | ||
| Q3 24 | $130.5M | $321.7M | ||
| Q2 24 | $132.2M | $315.3M | ||
| Q1 24 | $134.5M | $314.2M |
总资产ASRTBCML
| Q4 25 | $267.0M | $2.6B | ||
| Q3 25 | $319.8M | $2.6B | ||
| Q2 25 | $273.8M | $2.6B | ||
| Q1 25 | $286.4M | $2.6B | ||
| Q4 24 | $284.7M | $2.7B | ||
| Q3 24 | $276.0M | $2.6B | ||
| Q2 24 | $279.4M | $2.6B | ||
| Q1 24 | $282.0M | $2.6B |
负债/权益比ASRTBCML
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.29× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-30.0M | $31.8M |
| 自由现金流经营现金流 - 资本支出 | — | $30.1M |
| 自由现金流率自由现金流/营收 | — | 116.2% |
| 资本支出强度资本支出/营收 | — | 6.7% |
| 现金转化率经营现金流/净利润 | — | 4.64× |
| 过去12个月自由现金流最近4个季度 | — | $51.1M |
8季度趋势，按日历期对齐
经营现金流ASRTBCML
| Q4 25 | $-30.0M | $31.8M | ||
| Q3 25 | $-4.8M | $7.3M | ||
| Q2 25 | $19.1M | $6.4M | ||
| Q1 25 | $-12.5M | $9.3M | ||
| Q4 24 | $11.5M | $30.4M | ||
| Q3 24 | $-35.0K | $9.6M | ||
| Q2 24 | $7.4M | $7.7M | ||
| Q1 24 | $7.5M | $5.1M |
自由现金流ASRTBCML
| Q4 25 | — | $30.1M | ||
| Q3 25 | — | $6.2M | ||
| Q2 25 | — | $5.6M | ||
| Q1 25 | — | $9.1M | ||
| Q4 24 | — | $28.7M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | — | $7.4M | ||
| Q1 24 | — | $3.9M |
自由现金流率ASRTBCML
| Q4 25 | — | 116.2% | ||
| Q3 25 | — | 24.3% | ||
| Q2 25 | — | 22.8% | ||
| Q1 25 | — | 37.6% | ||
| Q4 24 | — | 121.1% | ||
| Q3 24 | — | 36.6% | ||
| Q2 24 | — | 31.2% | ||
| Q1 24 | — | 16.1% |
资本支出强度ASRTBCML
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 4.3% | ||
| Q2 25 | — | 3.0% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 7.2% | ||
| Q3 24 | 0.0% | 1.0% | ||
| Q2 24 | — | 1.0% | ||
| Q1 24 | — | 4.7% |
现金转化率ASRTBCML
| Q4 25 | — | 4.64× | ||
| Q3 25 | -0.42× | 1.47× | ||
| Q2 25 | — | 1.00× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 4.96× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.37× | ||
| Q1 24 | — | 0.86× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASRT
| Products | $12.8M | 95% |
| Other | $719.0K | 5% |
BCML
暂无分部数据
